Pub Date : 2026-01-01Epub Date: 2026-01-27DOI: 10.1016/j.abd.2025.501254
Hongjie Jiang , Pan Wei , Zhixiu Xu , Yan Chen , Binbin Li
Background
Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease with heterogeneous clinical manifestations that is hard to diagnose. Direct immunofluorescence (DIF) is critical, but its role in multimodal frameworks is unclear.
Objective
To assess DIF's diagnostic performance in MMP and explore factors affecting its positivity patterns in multimodal workflows.
Methods
We retrospectively analyzed 79 suspected MMP patients, categorizing them into confirmed and non-confirmed groups based on clinical, histopathological, and serological criteria. DIF of perilesional mucosal biopsies showed linear deposits of IgG, IgA, IgM, C3, and fibrinogen along the basement membrane zone (BMZ). Diagnostic efficacy was assessed via ROC curve analysis.
Results
55 cases were confirmed. Histopathology demonstrated subepithelial blisters in 51, with 100% specificity, 92.73% sensitivity (AUC = 0.964, p < 0.05). DIF identified 47 cases, with C3 (63.64%) and IgG (60.00%) most common, showing 85.45% sensitivity, 100% specificity, and 97.87% concordance with histopathology. Disease duration independently predicted positive IgM (p = 0.023).
Study limitations
However, this study is a single-center retrospective study with a limited sample size, which has certain limitations.
Conclusion
DIF, 100% specific, aids histopathology in MMP diagnosis, especially with C3/IgG linear BMZ deposition. Notably, IgM positivity correlates with prolonged disease duration, suggesting DIF efficiency may link to disease stage.
粘膜类天疱疮（MMP）是一种自身免疫性水疱病，临床表现异质性，难以诊断。直接免疫荧光（DIF）至关重要，但其在多模式框架中的作用尚不清楚。目的评价DIF对MMP的诊断效果，探讨其在多模式工作流程中阳性模式的影响因素。方法回顾性分析79例疑似MMP患者，根据临床、组织病理学和血清学标准将其分为确诊组和非确诊组。病灶周围粘膜活检的DIF显示沿基底膜区（BMZ）有IgG、IgA、IgM、C3和纤维蛋白原的线性沉积。通过ROC曲线分析评估诊断效果。结果共确诊55例。51例组织病理学表现为上皮下水疱，特异性100%，敏感性92.73% （AUC = 0.964, p < 0.05）。DIF检出47例，以C3（63.64%）和IgG（60.00%）最常见，敏感性85.45%，特异性100%，与组织病理学一致性97.87%。病程独立预测IgM阳性（p = 0.023）。但本研究为单中心回顾性研究，样本量有限，存在一定的局限性。结论dif具有100%的特异性，有助于组织病理学诊断MMP，特别是C3/IgG线性BMZ沉积。值得注意的是，IgM阳性与疾病持续时间延长相关，这表明DIF效率可能与疾病分期有关。
{"title":"Diagnostic value of direct immunofluorescence in oral mucous membrane pemphigoid: a retrospective study","authors":"Hongjie Jiang , Pan Wei , Zhixiu Xu , Yan Chen , Binbin Li","doi":"10.1016/j.abd.2025.501254","DOIUrl":"10.1016/j.abd.2025.501254","url":null,"abstract":"<div><h3>Background</h3><div>Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease with heterogeneous clinical manifestations that is hard to diagnose. Direct immunofluorescence (DIF) is critical, but its role in multimodal frameworks is unclear.</div></div><div><h3>Objective</h3><div>To assess DIF's diagnostic performance in MMP and explore factors affecting its positivity patterns in multimodal workflows.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 79 suspected MMP patients, categorizing them into confirmed and non-confirmed groups based on clinical, histopathological, and serological criteria. DIF of perilesional mucosal biopsies showed linear deposits of IgG, IgA, IgM, C3, and fibrinogen along the basement membrane zone (BMZ). Diagnostic efficacy was assessed via ROC curve analysis.</div></div><div><h3>Results</h3><div>55 cases were confirmed. Histopathology demonstrated subepithelial blisters in 51, with 100% specificity, 92.73% sensitivity (AUC = 0.964, p < 0.05). DIF identified 47 cases, with C3 (63.64%) and IgG (60.00%) most common, showing 85.45% sensitivity, 100% specificity, and 97.87% concordance with histopathology. Disease duration independently predicted positive IgM (p = 0.023).</div></div><div><h3>Study limitations</h3><div>However, this study is a single-center retrospective study with a limited sample size, which has certain limitations.</div></div><div><h3>Conclusion</h3><div>DIF, 100% specific, aids histopathology in MMP diagnosis, especially with C3/IgG linear BMZ deposition. Notably, IgM positivity correlates with prolonged disease duration, suggesting DIF efficiency may link to disease stage.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501254"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-09DOI: 10.1016/j.abd.2025.501271
José Antonio Jabur da Cunha , Roberto Gomes Tarle , Glaysson Tassara Tavares
{"title":"Letter to the Editor regarding: “Pre-and post-analytical guidelines for the microscopic diagnosis of melanoma: recommendations from the Brazilian Society of Pathology”","authors":"José Antonio Jabur da Cunha , Roberto Gomes Tarle , Glaysson Tassara Tavares","doi":"10.1016/j.abd.2025.501271","DOIUrl":"10.1016/j.abd.2025.501271","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501271"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-08DOI: 10.1016/j.abd.2025.501253
Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião
Background
Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent.
Objective
To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL.
Methods
The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.
Results
Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71–0.98; I2 = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36–43.12), and fever (RR = 2.98; 95% CI: 1.53–5.80) were more common with meglumine antimoniate.
Study Limitations
High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision.
Conclusion
Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.
{"title":"Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis","authors":"Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião","doi":"10.1016/j.abd.2025.501253","DOIUrl":"10.1016/j.abd.2025.501253","url":null,"abstract":"<div><h3>Background</h3><div>Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent.</div></div><div><h3>Objective</h3><div>To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL.</div></div><div><h3>Methods</h3><div>The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.</div></div><div><h3>Results</h3><div>Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71–0.98; <em>I</em><sup>2</sup> = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36–43.12), and fever (RR = 2.98; 95% CI: 1.53–5.80) were more common with meglumine antimoniate.</div></div><div><h3>Study Limitations</h3><div>High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision.</div></div><div><h3>Conclusion</h3><div>Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501253"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-19DOI: 10.1016/j.abd.2025.501272
José Cândido Caldeira Xavier-Júnior , Karina Munhoz de Paula Alves Coelho , Mariana Petaccia de Macedo , Rute Facchini Lellis , Nathanael de Freitas Pinheiro Junior , Robledo Fonseca Rocha , Comitê de Dermatopatologia da Sociedade Brasileira de Patologia
{"title":"Letter to the Editor regarding: “Pre- and post-analytical guidelines for the microscopic diagnosis of melanoma: recommendations from the Brazilian Society of Pathology” – Reply","authors":"José Cândido Caldeira Xavier-Júnior , Karina Munhoz de Paula Alves Coelho , Mariana Petaccia de Macedo , Rute Facchini Lellis , Nathanael de Freitas Pinheiro Junior , Robledo Fonseca Rocha , Comitê de Dermatopatologia da Sociedade Brasileira de Patologia","doi":"10.1016/j.abd.2025.501272","DOIUrl":"10.1016/j.abd.2025.501272","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501272"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on “The relationship of FricTest® responses with an urticaria activity score, urticaria control test and quality of life scales in patients with symptomatic dermographism”","authors":"Prajnasini Satapathy , Rachana Mehta , Ranjana Sah","doi":"10.1016/j.abd.2025.501285","DOIUrl":"10.1016/j.abd.2025.501285","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501285"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-24DOI: 10.1016/j.abd.2025.501255
Heba Saed El-Amawy
Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and has demonstrated significant efficacy in glycemic control and weight reduction. Beyond its metabolic benefits, recent evidence highlights its relevance in dermatology. This review explores the dermatologic implications of tirzepatide, including its cutaneous adverse effects, therapeutic potential in inflammatory skin diseases, and cosmetic benefits. Cutaneous side effects such as hypersensitivity reactions, injection-site reactions, and rare severe dermatologic events have been documented. Across the SURPASS clinical trials, injection-site reactions occurred slightly more frequently, comparable to other GLP-1 receptor agonists as semaglutide. Meanwhile, tirzepatide's immunomodulatory properties suggest potential therapeutic roles in conditions like psoriasis and hidradenitis suppurativa; however, current evidence is limited to case reports and small studies. Additionally, its profound effects on fat distribution raise interest in its cosmetic implications. Tirzepatide's induced rapid weight loss may lead to aesthetic changes, including facial volume loss, which warrants cautious interpretation. This narrative review summarizes current data from clinical trials, case reports, and pharmacovigilance sources, based on a literature search of PubMed, Scopus, and Google Scholar up to May 2025, focusing on skin-related adverse events, therapeutic effects, and cosmetic outcomes of tirzepatide.
{"title":"Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review","authors":"Heba Saed El-Amawy","doi":"10.1016/j.abd.2025.501255","DOIUrl":"10.1016/j.abd.2025.501255","url":null,"abstract":"<div><div>Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and has demonstrated significant efficacy in glycemic control and weight reduction. Beyond its metabolic benefits, recent evidence highlights its relevance in dermatology. This review explores the dermatologic implications of tirzepatide, including its cutaneous adverse effects, therapeutic potential in inflammatory skin diseases, and cosmetic benefits. Cutaneous side effects such as hypersensitivity reactions, injection-site reactions, and rare severe dermatologic events have been documented. Across the SURPASS clinical trials, injection-site reactions occurred slightly more frequently, comparable to other GLP-1 receptor agonists as semaglutide. Meanwhile, tirzepatide's immunomodulatory properties suggest potential therapeutic roles in conditions like psoriasis and hidradenitis suppurativa; however, current evidence is limited to case reports and small studies. Additionally, its profound effects on fat distribution raise interest in its cosmetic implications. Tirzepatide's induced rapid weight loss may lead to aesthetic changes, including facial volume loss, which warrants cautious interpretation. This narrative review summarizes current data from clinical trials, case reports, and pharmacovigilance sources, based on a literature search of PubMed, Scopus, and Google Scholar up to May 2025, focusing on skin-related adverse events, therapeutic effects, and cosmetic outcomes of tirzepatide.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501255"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145838906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-08DOI: 10.1016/j.abd.2025.501258
Ana Luisa Sampaio , Bruna Romana-Souza , Haizza Monteiro , Jeane de Souza Nogueira , Danielle Angst Secco , Gilson Costa dos Cantos Jr. , Andrea Monte-Alto-Costa , Flavia Cassia , Sueli Carneiro , Luna Azulay-Abulafia , Luis Cristóvão Porto
Background
Psoriasis is a chronic, immune-mediated disease with a significant genetic component. The HLA-C*06:02 allele is one of the most strongly associated with the disease, particularly influencing early onset and severity. There are few current data on genetics in a Brazilian population with psoriasis.
Objective
This study aimed to investigate the genetic associations between human leucocyte antigen (HLA) alleles and psoriasis in a Brazilian admixed population.
Methods
The authors conducted HLA class I and II genotyping in 144 patients with psoriasis and compared the results with those of 720 controls. Additionally, the authors calculated the Psoriasis Area and Severity Index (PASI) and recorded whether the patient had current or previous systemic treatment for psoriasis and the age of disease onset.
Results
HLA-B*13:02g, B*15:01g, B*37:01g, B*38:01g, B*57:01g, B*57:02g, B*13:02g, C*01:02g, C*06:02g, C*12:03g, C*18:01g, DRB1*01:02g, DRB1*04:08g and DPB1*04:01g alleles were associated with an increased risk of psoriasis (after the Bonferroni correction factor, only the HLA-C*06:02 remained significant). And HLA-DRB1*15:03g conferred protection against psoriasis after Bonferroni correction. Alleles significantly associated with PASI score < 10 were A*34:02g (p = 0.037) and B*50:01g (p = 0.037), while the allele related to PASI > 10 was DRB1*01:01g (p = 0.049). When comparing the age of disease onset, the following alleles were significantly associated with early onset psoriasis (before 30 years of age): B*44:03g (p = 0.010) and C*07:02g (p = 0.022).
Study limitations
The sample size was small compared with other international publications, and the subgroup of patients with mild disease was less represented; however, the combination of analytical approaches (univariate tests, PCA, and correction for multiple comparisons) reinforces the robustness of the work.
Conclusion
The present findings highlight the genetic complexity of psoriasis in a diverse population and suggest that it may not be directly linked to specific genetic factors. Further research is required to explore the environmental and genetic interactions that contribute to psoriasis pathogenesis.
{"title":"Frequency of HLA class I and II in an admixed Brazilian population with psoriasis","authors":"Ana Luisa Sampaio , Bruna Romana-Souza , Haizza Monteiro , Jeane de Souza Nogueira , Danielle Angst Secco , Gilson Costa dos Cantos Jr. , Andrea Monte-Alto-Costa , Flavia Cassia , Sueli Carneiro , Luna Azulay-Abulafia , Luis Cristóvão Porto","doi":"10.1016/j.abd.2025.501258","DOIUrl":"10.1016/j.abd.2025.501258","url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis is a chronic, immune-mediated disease with a significant genetic component. The HLA-C*06:02 allele is one of the most strongly associated with the disease, particularly influencing early onset and severity. There are few current data on genetics in a Brazilian population with psoriasis.</div></div><div><h3>Objective</h3><div>This study aimed to investigate the genetic associations between human leucocyte antigen (HLA) alleles and psoriasis in a Brazilian admixed population.</div></div><div><h3>Methods</h3><div>The authors conducted HLA class I and II genotyping in 144 patients with psoriasis and compared the results with those of 720 controls. Additionally, the authors calculated the Psoriasis Area and Severity Index (PASI) and recorded whether the patient had current or previous systemic treatment for psoriasis and the age of disease onset.</div></div><div><h3>Results</h3><div>HLA-<em>B</em>*13:02g, <em>B</em>*15:01g, <em>B</em>*37:01g, <em>B</em>*38:01g, <em>B</em>*57:01g, <em>B</em>*57:02g, <em>B</em>*13:02g, <em>C</em>*01:02g, <em>C</em>*06:02g, <em>C</em>*12:03g, <em>C</em>*18:01g, <em>DRB1</em>*01:02g, <em>DRB1</em>*04:08g and <em>DPB1</em>*04:01g alleles were associated with an increased risk of psoriasis (after the Bonferroni correction factor, only the HLA-<em>C</em>*06:02 remained significant). And HLA-<em>DRB1</em>*15:03g conferred protection against psoriasis after Bonferroni correction. Alleles significantly associated with PASI score < 10 were <em>A</em>*34:02g (p = 0.037) and <em>B</em>*50:01g (p = 0.037), while the allele related to PASI > 10 was <em>DRB1</em>*01:01g (p = 0.049). When comparing the age of disease onset, the following alleles were significantly associated with early onset psoriasis (before 30 years of age): <em>B</em>*44:03g (p = 0.010) and <em>C</em>*07:02g (p = 0.022).</div></div><div><h3>Study limitations</h3><div>The sample size was small compared with other international publications, and the subgroup of patients with mild disease was less represented; however, the combination of analytical approaches (univariate tests, PCA, and correction for multiple comparisons) reinforces the robustness of the work.</div></div><div><h3>Conclusion</h3><div>The present findings highlight the genetic complexity of psoriasis in a diverse population and suggest that it may not be directly linked to specific genetic factors. Further research is required to explore the environmental and genetic interactions that contribute to psoriasis pathogenesis.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"101 1","pages":"Article 501258"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号